Clinical TrialID 5342

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

NCT04325880

Ureteral Stent|Stent Related Symptoms

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5342
Evidence Id
5342
Core Evidence Id
5342
Source Clinical Trial Id
5328
Herb2 Clinical Trial Id
HBCT005328
Nct Id
NCT04325880
Title
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Status
Phase
Phase 3
Study Result
No
Study Condition
Ureteral Stent|Stent Related Symptoms
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT
Intervention
DRUG: Mirabegron 50 MG|DRUG: Tamsulosin|DRUG: Solifenacin Succinate 10 MG|DRUG: Placebo oral tablet
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Double
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
240
Outcome Measure
Improvement in stent related symptoms using ureteral stent symptoms questionnaire (USSQ), The effect of the assigned treatment on improvement of stent related symptoms will be assessed at the time of stent removal using ureteral stent symptoms questionnaire (USSQ), 4 weeks
Sponsor Collaborator
Mansoura University
Funded By
OTHER
Location
Urology and Nephrology Center, Mansoura, DK, 35516, Egypt
Other Id
AE 24320
Start Date
2021-12-01
Primary Completion Date
2022-06-01
Completion Date
2022-07-01
First Posted
2020-03-30
Results First Posted
Last Update Posted
2021-11-23
Study Document
Study Url
https://clinicaltrials.gov/study/NCT04325880
Title Cn
Title En
Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms
Bilingual Status
semi_complete